Clinical characteristics and viral load dynamics of COVID-19 in a mildly or moderately symptomatic outpatient sample

PLoS One. 2021 Oct 21;16(10):e0258970. doi: 10.1371/journal.pone.0258970. eCollection 2021.

Abstract

Background: Studies of outpatients with mild or moderate COVID-19 are uncommon. We studied: 1) association of symptoms with reverse transcriptase polymerase chain reaction (RT-PCR) test results; and 2) association of initial RT-PCR cycle threshold (Ct) in relation to duration of RT-PCR positivity in outpatients with mild or moderate COVID-19.

Methods: This was a cohort study of outpatients with confirmed COVID-19 and at least one symptom. Participants had repeat nasopharyngeal swabs and symptom checklists every 3-5 days until two consecutive RT-PCR tests were negative. RT-PCR tests were used to assess viral load. Antibody tests for COVID-19 were performed at 2 weeks, 4 weeks, and 8 weeks after symptom onset.

Results: Twenty-five patients (nine females) were enrolled, ranging in age from 19-58 (median age 28 years). All patients reported at least one symptom, with a median of six symptoms per patient. Symptoms persisted for 6-67 days (median duration 18 days). In all 25 patients, blood samples collected a median of 13 days after symptom onset were positive for SARS-CoV-2 antibodies in 15 (60%). After a median of 28 days following symptom onset, 23/23 patients with available samples tested positive for antibodies. The longest duration of positive RT-PCR test was 49 days from first positive PCR test (Mean = 27.4, SD = 12.5, Median = 24). Initial Ct was significantly associated with longer duration (β = -1.3, SE = 0.3, p<0.01 per 1 cycle higher) of RT-PCR positivity.

Conclusions: In mildly or moderately ill COVID-19 outpatients, RT-PCT tests remained positive for as long as 49 days and test positivity and symptom duration correlated with initial viral load.

MeSH terms

  • Adult
  • Antibodies, Viral / blood*
  • COVID-19 Nucleic Acid Testing
  • COVID-19 Serological Testing*
  • COVID-19* / blood
  • COVID-19* / diagnosis
  • COVID-19* / epidemiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Outpatients*
  • Reverse Transcriptase Polymerase Chain Reaction*
  • SARS-CoV-2 / metabolism*
  • Viral Load*

Substances

  • Antibodies, Viral

Grants and funding

The author(s) received no specific funding for this work.